Expert Interview
Dissecting the Phase 3 Results of Regeneron's Olatorepatide (once-weekly GLP-1/GIP receptor dual agonist) for Obesity Treatment
Ticker(s): REGN, LLY, NVO, VKTX, PFEInstitution: Yale School of Medicine
- Assistant Professor at Yale University in the Section of Endocrinology
- Manages over 100+ patients annually with Type 2 Diabetes and Obesity
- Possesses additional training in obesity medicine and weight management; Research focus involves the comprehensive management of the interrelated disease processes of diabetes, obesity, and sleep disorders.
How does Olatorepatide compare to GLP-1 medications which are already approved?
Added By: max_adminHow do you interpret Olatorepatide's Phase 3 Results?
Added By: ben_adminRank your excitement for Olatorepatide on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
